Cardiovascular therapeutics
[4] [5] Appropriate clinical management for patients with comorbid metabolic conditions and problematic alcohol use should include: Comprehensive assessment of alcohol consumption patterns using validated screening tools (AUDIT, AUDIT-C) Referral to addiction medicine specialists or behavioral health providers for evidence-based AUD treatment, especially with red flags such as history of severe withdrawal, seizures, delirium tremens, pregnancy, severe liver disease, or suicidality Consideration of FDA-approved pharmacotherapies for alcohol use disorder (naltrexone, acamprosate, disulfiram) with attention to their specific contraindications [9] [11] If GLP-1 therapy is indicated for diabetes or obesity, close monitoring for changes in alcohol consumption and related behaviors Patient education emphasizing that any effects on alcohol cravings are not established therapeutic benefits Regular follow-up to assess medication adherence, adverse effects, and overall treatment response Patients should never discontinue evidence-based treatments for alcohol use disorder in favor of unproven approaches
However, a significant challenge in evaluating kidney outcomes lies in the inconsistent definitions of renal endpoints across studies, particularly regarding the thresholds for substantial eGFR decline, which vary from 30% to 57%
Cravings ease, heavy-drinking days drop, and many people regain a sense of control over their drinking
It may take time and a little trial and error
But for millions of people, the biggest barrier to treatment hasn't been motivation
